The Beat AML Master Trial found high remission rates and promising safety with triplet therapy in patients with acute myeloid leukemia (AML), according to Ashley Yocum, PhD. In part 2 of an interview ...
Scientists from the German Cancer Research Center (DKFZ) and the HI-STEM* Stem Cell Institute have deciphered a key mechanism ...
Sellas Life Sciences’ investigational CDK9 inhibitor has scored in a midstage acute myeloid leukemia (AML) study, demonstrating an overall response rate (ORR) more than double the 20% goal. The ...
An international team of scientists has uncovered a mechanism by which acute myeloid leukemia (AML) cells sustain their growth. AML cells prevent the synthesis of proteins that suppress their growth ...
(RTTNews) - Shares of SELLAS Life Sciences Group Inc. (SLS) are up nearly 7% at $1.86 in premarket trading, following promising clinical data from its ongoing Phase 2 study of SLS009 in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results